Non-neoplastic conditions mimicking peritoneal carcinomatosis at CT imaging

Elmohr, Mohab M.; Elsayes, Khaled M.; Pickhardt, Perry J.

doi:10.1259/bjr.20200401

Cited by 13 publications

(3 citation statements)

References 77 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Nevertheless, like mentioned in our case, peritoneal tuberculosis mimicked peritoneal carcinomatosis in several ways. Both show multiple peritoneal nodules and irregular omental thickening and soft tissue attenuation [10] , as well as a misleading elevated serum levels of CA 125 [11] .…”

Section: Discussionmentioning

confidence: 99%

Peritoneal thickening: It's not always carcinomatosis

Amalik

Hajar

Khouchoua

et al. 2021

Radiology Case Reports

View full text Add to dashboard Cite

The peritoneal pseudotumor localization of tuberculosis is a rare clinical form, representing 1 to 3% of extrapulmonary site of tuberculosis. It represents the sixth most common extra pulmonary site of tuberculosis. It is a great mimicker with major overlapping clinical and imaging features. Differentiating peritoneal tuberculosis and peritoneal carcinomatosis in imaging remains challenging. We present a case of a 37-year old woman complaining of chronic abdominal pain and distension who has been diagnosed to have peritoneal carcinomatosis based on CT findings, histopathological study then revealed necrotizing, granulomatous inflammation consistent with tuberculosis. This case showed the interest to be aware of the common and uncommon imaging features of tuberculosis by radiologists to better assess for alternative differential diagnosis.

show abstract

Section: Discussionmentioning

confidence: 99%

Peritoneal thickening: It's not always carcinomatosis

Amalik

Hajar

Khouchoua

et al. 2021

Radiology Case Reports

View full text Add to dashboard Cite

show abstract

“…Peritoneal tuberculosis [4] Actinomycosis [6] Splenosis implants [4] Endometriosis [6] Foreign body reaction [7] has significantly improved the life expectancy of patients. Depending on the type of primary malignancy, the increase in survival has been from 3-24 to 40-62 months [27].…”

Section: Table 2 Peritoneal Carcinomatosis -Differential Diagnoses 1 ...mentioning

confidence: 99%

Diagnosis and treatment of peritoneal carcinomatosis – a comprehensive overview

Szadkowska¹,

Pałucki²,

Cieszanowski³

2023

Pol J Radiol

View full text Add to dashboard Cite

Peritoneal carcinomatosis, which is the most common malignant process of the peritoneal cavity, originates mostly from colorectal, gastric, and gynaecological malignancies. The differential diagnosis is broad and covers primary peritoneal malignancies, as well as many benign disorders such as endometriosis, and inflammatory and infectious diseases. Peritoneal implants tend to locate in the areas of the physiological stasis of the peritoneal fluid: pelvic peritoneal reflections, right and left paracolic gutters, superior part of the sigmoid mesocolon, ileocolic area, and the right subdiaphragmatic space. The 3 most common imaging findings are ascites, nodular implants, and infiltration of the peritoneal fatty tissue. Several imaging modalities may be applied in patients with peritoneal carcinomatosis. Ultrasound has low sensitivity and specificity, and therefore plays only a marginal role. Computed tomography is the method of choice, due to its availability, cost-effectiveness, and relatively high sensitivity. The sensitivity of magnetic resonance imaging depends on the size of peritoneal implants -in cases of implants larger than 10 mm is comparable to CT. Some studies suggest that PET/CT may be the most sensitive method, yet its usefulness in everyday practice is controversial. The Peritoneal Carcinomatosis Index (PCI) is a scale used to assess the tumour burden in the peritoneum and may serve as a communication tool between clinicians and radiologists. The imaging findings may influence the surgeon's decision on performing cytoreductive surgery, which may be followed by intraperitoneal chemotherapy (HIPEC or EPIC procedures). The introduction of these therapeutic methods has significantly improved the life expectancy of patients with peritoneal carcinomatosis.

show abstract

“…In this review, we will briefly summarize the current cancer imaging techniques used in clinical practice for cancer detection, interventions, and treatment evaluation. This will be followed by a discussion on the challenges and limitations of small lesions (MRI and US), suboptimal image resolution (PET, US, MR spectroscopy [approximately 100 mm] [26], MR cholangiography [approximately 1 mm] [27]), radiation exposure (CT, PET, SPECT), contrast agent toxicity (gadoliniumenhanced MRI), signal specificity (ie, between inflammation or atypical infection) (CT, MRI, PET) (20,(28)(29)(30)(31)(32)(33), and limited depth penetration (US [approximately 1 cm] and optical imaging [,5 mm]) (34). A known limitation of fluorine 18 ( 18 F) fluorodeoxyglucose (FDG) PET in cancer imaging is distinguishing between cancer and inflammatory processes.…”

mentioning

confidence: 99%

Nanotechnology for Cancer Imaging: Advances, Challenges, and Clinical Opportunities

Liu

Grodzinski

2021

Radiology: Imaging Cancer

View full text Add to dashboard Cite

Nanoparticle (NP) imaging applications have the potential to improve cancer diagnostics, therapeutics, and treatment management. In biomedical research and clinical practice, NPs can serve as labels or labeled carriers for monitoring drug delivery or serve as imaging agents for enhanced imaging contrast, as well as providing improved signal sensitivity and specificity for in vivo imaging of molecular and cellular processes. These qualities offer exciting opportunities for NP-based imaging agents to address current limitations in oncologic imaging. Despite substantial advancements in NP design and development, very few NP-based imaging agents have translated into clinics within the past 5 years. This review highlights some promising NP-enabled imaging techniques and their potential to address current clinical cancer imaging limitations. Although most examples provided herein are from the preclinical space, discussed imaging solutions could offer unique in vivo tools to solve biologic questions, improve cancer treatment effectiveness, and inspire clinical translation innovation to improve patient care.

show abstract

Non-neoplastic conditions mimicking peritoneal carcinomatosis at CT imaging

Cited by 13 publications

References 77 publications

Peritoneal thickening: It's not always carcinomatosis

Peritoneal thickening: It's not always carcinomatosis

Diagnosis and treatment of peritoneal carcinomatosis – a comprehensive overview

Nanotechnology for Cancer Imaging: Advances, Challenges, and Clinical Opportunities

Contact Info

Product

Resources

About